Invex Therapeutics (ASX:IXC) Total Payout Yield % : 0.00 (As of Jun. 23, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Invex Therapeutics's current Total Payout Yield % is 0.00%.

Invex Therapeutics Total Payout Yield % Historical Data

The historical data trend for Invex Therapeutics's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Total Payout Yield % Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Total Payout Yield %

-16.45

-17.10

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Payout Yield %	Get a 7-Day Free Trial				-	-	-	-	459.99

Competitive Comparison of Invex Therapeutics's Total Payout Yield %

For the Biotechnology subindustry, Invex Therapeutics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Total Payout Yield % falls into.

Invex Therapeutics Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Invex Therapeutics's Total Payout Yield % for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0	+	0)	/	15.03076
	=	0.00%

Invex Therapeutics's annualized Total Payout Yield % for the quarter that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (-14.001	+	0	+	0)	*	2	/	6.0874578
	=	459.99%

Invex Therapeutics Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Invex Therapeutics Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics (ASX:IXC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.